Novo Nordisk shares rebound despite disappointing CagriSema trial results

Novo Nordisk's CagriSema trial showed disappointing weight loss results, leaving room for Lilly to maintain dominance in the obesity treatment market with its competing therapies.

Novo Nordisk sinks on latest data, Lilly gains

Novo Nordisk shares fell nearly 28% after CagriSema's trial results showed lower than expected weight loss, while Eli Lilly's shares rose 10% amidst the news.

Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints

Novo Nordisk's obesity drug CagriSema showed a 22.7% weight loss in trials, disappointing investors and causing a significant drop in market value amid fierce competition.

Denmark stocks lower at close of trade; OMX Copenhagen 20 down 2.82%

Denmark stocks fell 2.82% with losses in Technology, Healthcare, and Real Estate sectors; falling stocks outnumbered advancers significantly.

EU regulator to review potential link between Ozempic and eye condition

EU to review studies linking Novo Nordisk's Ozempic to rare eye condition

The EMA is reviewing studies linking Novo Nordisk's Ozempic diabetes drug to a rare eye condition, although no direct cause-and-effect relationship has been established yet.

Denmark seeks EU review of Ozempic over vision loss concern

The Danish Medicines Agency requests a PRAC review of Ozempic due to potential links to vision loss and increased NAION risk, following new studies indicating health concerns.

Novo Nordisk to invest $1.2 billion in new plant in Denmark

Novo Nordisk is investing $1.20 billion in a modular facility in Odense, Denmark for the production of drugs for rare diseases, set to be completed by 2027.

Denmark stocks lower at close of trade; OMX Copenhagen 20 down 2.58%

Denmark stocks fell 2.58% driven by losses in healthcare and technology, with notable drops from Novo Nordisk and Genmab, while crude and Brent oil prices increased.

Ozempic linked to vision loss risk in new study

A study links Ozempic, a diabetes medication, to a doubled risk of rare vision loss (NAION). Novo Nordisk maintains a positive risk-benefit profile despite this finding.